GSK Jun 2024 47.000 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

2.1500

0.0000

(0.00%)

As of 03:39PM EDT. Market open.

Business Wire
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
PHILADELPHIA, June 07, 2024--US FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk
Insider Monkey
The City With the highest HIV/AIDS Rates in the US
We recently compiled a list of 20 Cities With the Highest HIV/AIDS Rates in the US and in this article, we will talk about the city with the highest HIV/AIDS rates in the US. HIV Incidence and Prevalence in the United States The government of the United States has set a goal to reduce the […]
Simply Wall St.
The total return for GSK (LON:GSK) investors has risen faster than earnings growth over the last year
The simplest way to invest in stocks is to buy exchange traded funds. But one can do better than that by picking better...